CYTOKINETICS INC

Form 4 March 16, 2006

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB

3235-0287 Number: January 31,

Expires: 2005 Estimated average

OMB APPROVAL

burden hours per

response... 0.5

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person * MORGANS DAVID J JR

280 EAST GRAND AVENUE

(Street)

(State)

2. Issuer Name and Ticker or Trading Symbol

CYTOKINETICS INC [CYTK]

5. Relationship of Reporting Person(s) to

Issuer

(Last)

(City)

(First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year)

03/15/2006

(Check all applicable)

SVP-Drug Discovery and Dev

Director 10% Owner _X__ Officer (give title Other (specify below)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

(Zip)

SOUTH SAN FRANCISCO, CA 94080

Table I - Non-Derivative	Securities Acquired	Disposed of o	r Ronoficially Owned
Table I - Noll-Derivative	Securiues Acquired	i. Disposea of, o	Denenciany Owned

Person

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	 3. Transaction Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		, , ,
Common Stock	03/15/2006	M	5,000	A	\$ 1	25,000	D	
Common Stock	03/15/2006	S(1)	5,000	D	\$ 7.01	20,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: CYTOKINETICS INC - Form 4

$\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number or of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Ame Underlying Sect (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	An or No of
Incentive Stock Option (right to buy)	\$ 1	03/15/2006		M		5,000	03/14/2001(2)	03/14/2011	Common Stock	4
Incentive Stock Option (right to buy)	\$ 0.58						11/14/2000(3)	11/14/2010	Common Stock	2
Incentive Stock Option (right to buy)	\$ 1.2						07/10/2002(4)	07/10/2012	Common Stock	5
Incentive Stock Option (right to buy)	\$ 1.2						05/21/2003(5)	05/21/2013	Common Stock	5
Incentive Stock Option (right to buy)	\$ 6.5						04/08/2004(6)	03/08/2014	Common Stock	3
Incentive Stock Option (right to buy)	\$ 6.59						04/11/2005(7)	04/11/2015	Common Stock	3
Incentive Stock Option (right to buy)	\$ 7.15						03/01/2006(8)	03/01/2016	Common Stock	1
Non-Qualified Stock Option (right to buy)	\$ 6.59						04/11/2005(7)	04/11/2015	Common Stock	1
Non-Qualified Stock Option (right to buy)	\$ 7.15						03/01/2006(8)	03/01/2016	Common Stock	4

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners 2

Edgar Filing: CYTOKINETICS INC - Form 4

Director 10% Owner Officer Other

MORGANS DAVID J JR 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080

SVP-Drug Discovery and Dev

Signatures

David J. Morgans, Jr. 03/16/2006 Ph.D.

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2005.
- (2) This option is immediately exercisable upon grant and shall vest as to 3,750 shares on 03/14/02 and the balance of 11,250 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/14/05.
- (3) This option is immediately exercisable upon grant and shall vest as to 20,000 shares on 10/18/01 and the balance of 60,000 divided into equal monthly installments thereafter such that the option shall be 100% vested on 10/18/04.
- (4) This option is immediately exercisable upon grant and shall vest as to 833 shares on 04/15/02 and the balance of 49,167 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/15/07.
- (5) This option is immediately exercisable upon grant and shall vest as to 1,135 shares on 04/01/03 and the balance of 53,365 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/07.
- (6) This option shall vest and become exercisable as to 708 shares on 04/08/04 and the balance of 33,292 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/08/08.
- (7) When the ISO and NQ dated 04/11/05 are combined for a total grant of 50,000 shares, the option shall vest and become exercisable as to 50,000 shares divided into equal monthly installments such that the option shall be 100% vested on 03/01/2009.
- (8) When the ISO and NQ dated 03/01/2006 are combined for a total grant of 60,000 shares, the option shall vest and become exercisable as to 60,000 shares divided into equal monthly installments such that the option shall be 100% vested on 03/01/2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3